Copyright
©The Author(s) 2022.
World J Diabetes. Jul 15, 2022; 13(7): 532-542
Published online Jul 15, 2022. doi: 10.4239/wjd.v13.i7.532
Published online Jul 15, 2022. doi: 10.4239/wjd.v13.i7.532
Groups | Before treatment | 1 mo after treatment | 3 mo after treatment |
Fovea | |||
Compaq group (n = 48) | 18.58 ± 3.80 | 18.23 ± 3.75 | 17.86 ± 4.12 |
Ranibizumab group (n = 48) | 19.14 ± 4.00 | 18.78 ± 4.24 | 18.47 ± 3.96 |
t value | -0.703 | -0.673 | -0.740 |
P value | 0.484 | 0.502 | 0.461 |
Parafovea | |||
Compaq group (n = 48) | 40.92 ± 5.73 | 40.51 ± 4.85 | 40.38 ± 5.22 |
Ranibizumab group (n = 48) | 40.40 ± 5.51 | 40.10 ± 5.28 | 39.56 ± 4.87 |
t value | 0.453 | 0.396 | 0.796 |
P value | 0.651 | 0.693 | 0.428 |
Overall macular area | |||
Compaq group (n = 48) | 39.64 ± 4.85 | 39.40 ± 4.77 | 38.78 ± 4.62 |
Ranibizumab group (n = 48) | 40.43 ± 5.18 | 39.93 ± 5.03 | 39.52 ± 4.85 |
t value | -0.771 | -0.530 | -0.765 |
P value | 0.442 | 0.598 | 0.446 |
- Citation: Li YF, Ren Q, Sun CH, Li L, Lian HD, Sun RX, Su X, Yu H. Efficacy and mechanism of anti-vascular endothelial growth factor drugs for diabetic macular edema patients. World J Diabetes 2022; 13(7): 532-542
- URL: https://www.wjgnet.com/1948-9358/full/v13/i7/532.htm
- DOI: https://dx.doi.org/10.4239/wjd.v13.i7.532